Neuland Laboratories Limited — PPTs, 05-08-2026: Investor Presentation

Neuland Labs kicked off FY27 with strong Q1 results!

1. **Business Performance:** Total Income soared 116.3% YoY to Rs. 650.1 Cr. PAT jumped an impressive 975.0% YoY to Rs. 147.4 Cr. EBITDA rose 448.2% YoY to Rs. 231.1 Cr, with margins expanding to 35.5%. Both CMS & GDS segments performed well, driven by commercial products. Key GDS growth drivers were Ezetimibe and Mirtazapine.

2. **Growth Drivers or Strategy:** Focus remains on consistent delivery to build long-term customer partnerships. The company is actively pursuing broader capability-led discussions and plans increased investment intensity to capitalize on market opportunities.

3. **Recent Developments:** Working capital days significantly improved to 84 (from 137). Q1FY27 saw a Capex outflow of Rs. 122 Cr, highlighting ongoing expansion. The company holds a net cash position of Rs. 308.5 Cr.

4. **Key Financial Metrics:** Total Income: Rs. 650.1 Cr | EBITDA: Rs. 231.1 Cr | PAT: Rs. 147.4 Cr | EPS: Rs. 114.9.

5. **Management Commentary / Outlook:** Q1 results were in line with expectations, marking a good start to the year. Management sees exciting pipeline developments and expects to boost investments based on new opportunities.